Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

@article{Olive2009InhibitionOH,
  title={Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer},
  author={Kenneth P. Olive and Michael A. Jacobetz and Christian J. Davidson and Aarthi Gopinathan and Dominick J O McIntyre and Davina Jean Honess and Basetti Madhu and Mae A. Goldgraben and Meredith E. Caldwell and David Allard and Kristopher K. Frese and Gina M. DeNicola and Christine Feig and Chelsea Combs and Stephen P. Winter and Heather Ireland-Zecchini and Stefanie Reichelt and William J. Howat and A-L Chang and Mousumi Dhara and Lifu Wang and Felix R{\"u}ckert and Robert Gr{\"u}tzmann and Christian Pilarsky and Kamel Izeradjene and Sunil R Hingorani and Pearl S Huang and Susan E. Davies and William Plunkett and Merrill J. Egorin and Ralph H. Hruban and Nigel Whitebread and Karen Mcgovern and Julian Robert James Adams and Christine A. Iacobuzio-Donahue and John R. Griffiths and David A. Tuveson},
  journal={Science},
  year={2009},
  volume={324},
  pages={1457 - 1461}
}
It's All in the Delivery Pancreatic cancer is almost universally associated with a poor prognosis, in part because the tumors are resistant to chemotherapeutic drugs. Working with a mouse tumor model that displays many features of the human disease, Olive et al. (p. 1457, published online 21 May; see the Perspective by Olson and Hanahan) found that the tumors were poorly vascularized, a factor likely to impede drug delivery. Treatment of the mice with the chemotherapeutic drug gemcitabine in… Expand
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
TLDR
JP1201, a Smac mimetic, is a potent enhancer of chemotherapy in robust mouse models of pancreatic cancer and combination of JP1201 with gemcitabine reduced primary and metastatic tumor burden in orthotopic xenograft and syngenic tumor models. Expand
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer
Therapy-resistance and postoperative recurrence are causes of the poor prognosis in pancreatic cancer. Conventional therapies have a limited impact on the control of pancreatic cancer, resulting inExpand
Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer
TLDR
Treatment with gemcitabine monophosphate significantly increased apoptosis of cancer cells, enabled reduction in the proportion of immunosuppressive tumor-associated macrophages and myeloid-derived suppressing cells, and did not increase expression of cancer stem cell markers. Expand
Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy.
TLDR
It is shown that in clinically relevant PDAC models, M-CPA effectively modulates stroma by increasing microvessel density, alleviating hypoxia, reducing matrix stiffness while maintaining the tumor-restraining function of extracellular matrix. Expand
Stromal biology and therapy in pancreatic cancer
TLDR
Stromal cells contained within the PDA tumour microenvironment represent an additional constituent to neoplastic cells that should be critically evaluated for optimal therapeutic development in preclinical models and early clinical trials. Expand
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
TLDR
Some of the most important advances in the comprehension of the tumor cell-autonomous and tumor microenvironment-related molecular mechanisms responsible for the resistance of pancreatic cancer to the proapoptotic activity of the classic chemotherapeutic agents and to the most novel anti-angiogenic drugs are discussed. Expand
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
TLDR
A graded response to priming is demonstrated in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer. Expand
GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment
TLDR
It is reported that the commercial SHH inhibitor GDC-0449 reverses fibroblast-induced resistance to doxorubicin in Smoothened (SMO)-positive pancreatic cancer cells by downregulating SHH signaling proteins. Expand
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models
TLDR
The results provide a proof-of-principle validation that HSP90i-based drug conjugates can overcome the notorious treatment resistance by utilizing the inherently high affinity of pancreatic cancer cells to H SP90 antagonists. Expand
Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance
TLDR
The sensitivities of the primary cells and PDX xenografts to gemcitabine were correlated with each other, and the gem citabine-resistant cells had a higher level of MCF2L expression, suggesting that MCF1L plays an important role in gemcitABine resistance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 43 REFERENCES
K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.
TLDR
This chapter reviews the methods used to explore issues of drug delivery, imaging, and preclinical trial design in the GEM models for pancreatic cancer, and hypothesize that results of these preclinical studies will inform the design of clinical trials for pancreatIC cancer patients. Expand
Drug resistance and the solid tumor microenvironment.
TLDR
How the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumormicroenvironment are described. Expand
Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer
TLDR
It is shown that down-regulation of endogenous TG2 by siRNA could effectively block the growth of PDAC and significantly enhanced the therapeutic efficacy of gemcitabine againstPDAC and inhibited metastatic spread of the disease. Expand
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
TLDR
The results indicate that IL-4 cytotoxin combined with gemcitabine may provide effective therapy for the treatment of patients with PDA and synergistic antitumor activity in vitro is exhibited in vitro. Expand
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
TLDR
Results from the experimental liver metastasis models indicate an important role for targeting TβRI/II kinase activity on tumor and liver microenvironment cells in suppressing liver metastases. Expand
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
TLDR
The MIA PaCa-2 and PANC-1 xenograft models may be useful for selecting potential candidates for therapy of human pancreatic cancer and major differences in tumor sensitivity were noted with diarylsulfonylureas (DSU) and taxol. Expand
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
TLDR
It is shown that Hh signaling is active in stromal cells surrounding Hh-expressing tumor epithelium in various mouse pancreatic cancer models, which support a paracrine model of HH-mediated tumorigenesis, in which tumor cells secrete Hh ligand to induce tumor-promoting Hh target genes in adjacent stroma. Expand
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
TLDR
It is reported that sonic hedgehog, a secreted hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pancreatic intraepithelial neoplasia (PanIN), and that maintenance of hedgehog signalling is important for aberrant proliferation and tumorigenesis. Expand
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
TLDR
Evidence is provided that expression of SHH influences tumor growth by contributing to the formation of desmoplasia in pancreatic cancer and it is shown that SHH affects the differentiation and motility of human pancreatic stellate cells and fibroblasts. Expand
Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice
TLDR
It is shown that blockade of VEGF receptor activation interferes with the survival of tumor endothelial cells, resulting in a reduction of primary pancreatic tumor growth in nude mice, and anti‐VEGF receptor‐2 therapy potentiates the tumoricidal effect of gemcitabine in this model. Expand
...
1
2
3
4
5
...